C4 Therapeutics, Inc. (C4T) has announced the appointment of Stephen Fawell, Ph.D. to its board of directors, while Malcolm Salter has decided to retire from the board after nearly a decade of service.
Dr. Fawell brings with him nearly 35 years of drug discovery experience, having most recently spent over a decade at AstraZeneca as Vice President, Head of Oncology Small Molecule Drug Discovery. During his tenure, he successfully transitioned more than 25 new drugs into clinical trials, advanced multiple drugs into late-stage development, and supported the development or approval of several well-known drugs such as Tagrisso®, Lynparza®, Calquence®, and Truqap®. He also played a role in building AstraZeneca's targeted protein degradation platform.
C4T's President and CEO, Andrew Hirsch, expressed excitement in welcoming Dr. Fawell to the board and emphasized his alignment with the company's focus on developing degrader medicines for patients in need.
Under Dr. Fawell's leadership, AstraZeneca successfully transitioned more than 25 new drugs into the clinic, advanced camizestrant, ceralasertib, and saruparib into late-stage development, and supported the development or approval of Tagrisso®, Lynparza®, Calquence®, and Truqap®.
C4 Therapeutics, a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, is progressing targeted oncology programs through clinical studies and leveraging its torpedo® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The company's degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets, and improve patient outcomes. As a result of these announcements, the company's shares have moved -1.7% on the market, and are now trading at a price of $6.32. If you want to know more, read the company's complete 8-K report here.
